StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report published on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright dropped their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating on the stock in a report on Wednesday, August 7th.
Get Our Latest Report on Minerva Neurosciences
Minerva Neurosciences Stock Down 2.1 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). On average, equities research analysts anticipate that Minerva Neurosciences will post -1.89 earnings per share for the current fiscal year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
See Also
- Five stocks we like better than Minerva Neurosciences
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- What is the Euro STOXX 50 Index?
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.